Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma
AVEO Initiates the Evaluation of Tivozanib in Combination with Bristol-Myers Squibb’s Opdivo® (nivolumab) in Advanced Renal Cell Carcinoma
CAMBRIDGE, MA, USA I August 15, 2016 I AVEO Oncology (NASDAQ.
Agilent Technologies to Build New Facility in Colorado, Increasing Pharmaceutical Manufacturing Capacity
Agilent Technologies to Build New Facility in Colorado, Increasing Pharmaceutical Manufacturing Capacity
SANTA CLARA, Calif.
Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
Vertex Provides Update on Ongoing Phase 3 Program for VX-661 in Combination with Ivacaftor for the Treatment of Cystic Fibrosis
BOSTON, MA, USA - August 15, 2016 - Vertex Pharmaceuticals Incorporated (Nasdaq.
Pain reliever eliminates Alzheimer's symptoms – in mice
Pain reliever eliminates Alzheimer's symptoms – in mice
Mefenamic acid is a non-steroidal anti-inflammatory drug, commonly used to relieve period pain.
Endo Announces OPANA® ER Regulatory Update
Endo Announces OPANA® ER Regulatory Update
 DUBLIN, Ireland -- August 12, 2016 -- Endo International plc (NASDAQ.
AstraZeneca sees big share price rise, but it's not all the CEO's making
AstraZeneca sees big share price rise, but it's not all the CEO's making
When AstraZeneca ($AZN) CEO Pascal Soriot warded off Pfizer’s hostile takeover, he promised to transform the company into something even better.
Biogen, Eisai move into Phase III with BACE inhibitor in Alzheimer’s
Biogen, Eisai move into Phase III with BACE inhibitor in Alzheimer’s
Partners Eisai and Biogen ($BIIB) are moving their oral beta-secretase cleaving enzyme (BACE) inhibitor E2609 into Phase III.
Novel lipid altering therapies will steer acute coronary syndrome market beyond $12 billion by 2022, says GlobalData
Novel lipid altering therapies will steer acute coronary syndrome market beyond $12 billion by 2022, says GlobalData
The acute coronary syndrome (ACS) market is set to rise from $7.
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer
SYDNEY, Australia -- August 11, 2016 -- Australian oncology-focused biotechnology company Novogen Ltd (ASX.
FDA Accepts Marathon Pharmaceuticals’ New Drug Applications for Deflazacort for the Treatment of Duchenne Muscular Dystrophy and Grants Priority Review
FDA Accepts Marathon Pharmaceuticals’ New Drug Applications for Deflazacort for the Treatment of Duchenne Muscular Dystrophy and Grants Priority Review
NORTHBROOK, IL, USA -- August 10, 2016 -- Marathon Pharmaceuticals, LLC, a biopharmaceutical company developing treatments for rare diseases, today announced the New Drug Applications (NDA) fo...
Valeant Under Criminal Investigation
Valeant Under Criminal Investigation
Federal prosecutors are investigating whether Valeant Pharmaceuticals International Inc.
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
Heron Therapeutics Announces U.S. FDA Approval of SUSTOL® (granisetron) Extended-Release Injection for the Prevention of Chemotherapy-Induced Nausea and Vomiting
SUSTOL is the first extended-release 5-HT3 receptor antagonist approved for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy and anthracy...
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand